{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:35:20Z","timestamp":1790757320422,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s10620-024-08667-4","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T13:02:40Z","timestamp":1728478960000},"page":"835-842","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Safety and Efficacy of Dapagliflozin in Recurrent Ascites: A Pilot Study"],"prefix":"10.1007","volume":"70","author":[{"given":"Virendra","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arka","family":"De","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishav","family":"Aggrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Charak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Bhagat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"key":"8667_CR1","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1002\/hep.1840080532","volume":"8","author":"RW Schrier","year":"1988","unstructured":"Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rod\u00e9s J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8:1151\u20131157.","journal-title":"Hepatology."},{"key":"8667_CR2","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.jhep.2015.07.004","volume":"63","author":"M Bernardi","year":"2015","unstructured":"Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 2015;63:1272\u20131284.","journal-title":"Journal of hepatology."},{"key":"8667_CR3","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s12072-023-10536-7","volume":"17","author":"V Singh","year":"2023","unstructured":"Singh V, De A, Mehtani R, Angeli P, Maiwall R, Satapathy S et al. Asia-Pacific association for study of liver guidelines on management of ascites in liver disease. Hepatol Int. 2023;17:792\u2013826.","journal-title":"Hepatology international."},{"key":"8667_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/gutjnl-2020-321790","volume":"70","author":"GP Aithal","year":"2021","unstructured":"Aithal GP, Palaniyappan N, China L, H\u00e4rm\u00e4l\u00e4 S, Macken L, Ryan JM et al. Guidelines on the management of ascites in cirrhosis. Gut. 2021;70:9\u201329.","journal-title":"Gut."},{"key":"8667_CR5","doi-asserted-by":"crossref","unstructured":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 69:406\u201360.","DOI":"10.1016\/j.jhep.2018.03.024"},{"key":"8667_CR6","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/hep.31884","volume":"74","author":"SW Biggins","year":"2021","unstructured":"Biggins SW, Angeli P, Garcia-Tsao G, Gin\u00e8s P, Ling SC, Nadim MK et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74:1014\u20131048.","journal-title":"Hepatology."},{"key":"8667_CR7","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40265-019-01148-3","volume":"79","author":"S Dhillon","year":"2019","unstructured":"Dhillon S. Dapagliflozin: A Review in Type 2 Diabetes. Drugs. 2019;79:1135\u20131146.","journal-title":"Drugs."},{"key":"8667_CR8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","volume":"141","author":"MN Kosiborod","year":"2020","unstructured":"Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S et al. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial. Circulation. 2020;141:90\u201399.","journal-title":"Circulation."},{"key":"8667_CR9","doi-asserted-by":"crossref","unstructured":"Hsiang JC, Wong VW. SGLT2 Inhibitors in Liver Patients. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2020; 18:2168\u201372 e2.","DOI":"10.1016\/j.cgh.2020.05.021"},{"key":"8667_CR10","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.3390\/jcm12062253","volume":"12","author":"Y Miyamoto","year":"2023","unstructured":"Miyamoto Y, Honda A, Yokose S, Nagata M, Miyamoto J. The Effects of SGLT2 Inhibitors on Liver Cirrhosis Patients with Refractory Ascites: A Literature Review. J Clin Med. 2023;12:2253.","journal-title":"J Clin Med."},{"key":"8667_CR11","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1002\/hep.31270","volume":"72","author":"I Montalvo-Gordon","year":"2020","unstructured":"Montalvo-Gordon I, Chi-Cervera LA, Garc\u00eda-Tsao G. Sodium-Glucose Cotransporter 2 Inhibitors Ameliorate Ascites and Peripheral Edema in Patients With Cirrhosis and Diabetes. Hepatology. 2020;72:1880\u20131882.","journal-title":"Hepatology."},{"key":"8667_CR12","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1093\/ckj\/sfab266","volume":"15","author":"Y Miyamoto","year":"2022","unstructured":"Miyamoto Y, Honda A, Yokose S, Nagata M, Miyamoto J. Weaning from concentrated ascites reinfusion therapy for refractory ascites by SGLT2 inhibitor. Clin Kidney J. 2022;15:831\u2013833.","journal-title":"Clin Kidney J."},{"key":"8667_CR13","doi-asserted-by":"publisher","first-page":"618","DOI":"10.14309\/ajg.0000000000000995","volume":"116","author":"GN Kalambokis","year":"2021","unstructured":"Kalambokis GN, Tsiakas I, Filippas-Ntekuan S, Christaki M, Despotis G, Milionis H. Empagliflozin Eliminates Refractory Ascites and Hepatic Hydrothorax in a Patient With Primary Biliary Cirrhosis. The American journal of gastroenterology. 2021;116:618\u2013619.","journal-title":"The American journal of gastroenterology."},{"key":"8667_CR14","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/hepr.13678","volume":"51","author":"H Yoshiji","year":"2021","unstructured":"Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K et al. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res. 2021;51:725\u2013749.","journal-title":"Hepatol Res."},{"key":"8667_CR15","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jhep.2011.04.027","volume":"56","author":"V Singh","year":"2012","unstructured":"Singh V, Dhungana SP, Singh B, Vijayverghia R, Nain CK, Sharma N et al. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. Journal of hepatology. 2012;56:348\u2013354.","journal-title":"Journal of hepatology."},{"key":"8667_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/cld.714","volume":"11","author":"S Saffo","year":"2018","unstructured":"Saffo S, Taddei T. SGLT2 inhibitors and cirrhosis: A unique perspective on the comanagement of diabetes mellitus and ascites. Clin Liver Dis (Hoboken). 2018;11:141\u2013144.","journal-title":"Clin Liver Dis (Hoboken)."},{"key":"8667_CR17","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1210\/clinem\/dgac558","volume":"107","author":"HL Li","year":"2022","unstructured":"Li HL, Tse YK, Chandramouli C, Hon NW, Cheung CL, Lam LY et al. Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock. J Clin Endocrinol Metab. 2022;107:3442\u20133451.","journal-title":"J Clin Endocrinol Metab."},{"key":"8667_CR18","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s11938-019-00229-2","volume":"17","author":"S Ekpanyapong","year":"2019","unstructured":"Ekpanyapong S, Reddy KR. Infections in Cirrhosis. Curr Treat Options Gastroenterol. 2019;17:254\u2013270.","journal-title":"Curr Treat Options Gastroenterol."},{"key":"8667_CR19","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1056\/NEJMra2021808","volume":"384","author":"JS Bajaj","year":"2021","unstructured":"Bajaj JS, Kamath PS, Reddy KR. The Evolving Challenge of Infections in Cirrhosis. The New England journal of medicine. 2021;384:2317\u20132330.","journal-title":"The New England journal of medicine."},{"key":"8667_CR20","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1053\/j.gastro.2018.12.005","volume":"156","author":"S Piano","year":"2019","unstructured":"Piano S, Singh V, Caraceni P, Maiwall R, Alessandria C, Fernandez J et al. Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. Gastroenterology. 2019;156:1368\u201380.e10.","journal-title":"Gastroenterology."},{"key":"8667_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13098-020-00545-z","volume":"12","author":"K Ohara","year":"2020","unstructured":"Ohara K, Masuda T, Morinari M, Okada M, Miki A, Nakagawa S et al. The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease. Diabetol Metab Syndr. 2020;12:37.","journal-title":"Diabetol Metab Syndr."},{"key":"8667_CR22","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/dom.13126","volume":"20","author":"KM Hallow","year":"2018","unstructured":"Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab. 2018;20:479\u2013487.","journal-title":"Diabetes Obes Metab."},{"key":"8667_CR23","doi-asserted-by":"publisher","first-page":"E563","DOI":"10.1152\/ajpendo.00086.2017","volume":"313","author":"L Tang","year":"2017","unstructured":"Tang L, Wu Y, Tian M, Sj\u00f6str\u00f6m CD, Johansson U, Peng XR et al. Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes. Am J Physiol Endocrinol Metab. 2017;313:E563\u2013E576.","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"8667_CR24","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1111\/dom.14488","volume":"23","author":"S Saffo","year":"2021","unstructured":"Saffo S, Kaplan DE, Mahmud N, Serper M, John BV, Ross JS et al. Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin. Diabetes Obes Metab. 2021;23:2402\u20132408.","journal-title":"Diabetes Obes Metab."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08667-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-024-08667-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08667-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:40:24Z","timestamp":1739972424000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-024-08667-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["8667"],"URL":"https:\/\/doi.org\/10.1007\/s10620-024-08667-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4739647\/v1","asserted-by":"object"}]},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,9]]},"assertion":[{"value":"14 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}